<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301403</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1041 Cessation</org_study_id>
    <secondary_id>A534252</secondary_id>
    <secondary_id>SMPH\MEDICINE\TOBACCO RE</secondary_id>
    <nct_id>NCT02301403</nct_id>
  </id_info>
  <brief_title>A Comparative Effectiveness RCT of Optimized Cessation Treatments</brief_title>
  <official_title>A Comparative Effectiveness RCT of Optimized Cessation Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      This study is a 2-arm randomized clinical trial (RCT). Participants motivated to quit smoking
      will be randomized to one of two treatments: 1) a Modern Usual Care (M-UC) vs. 2)
      Abstinence-Optimized Cessation Treatment (AOCT). The components for the optimized treatment
      have strong theoretical and empirical support from the investigators previous screening
      studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ultimate goal of this research is to develop a chronic care treatment package for smokers
      that will address the challenges and opportunities of each phase of the cessation process -
      motivation, preparation, cessation, maintenance, and relapse recovery. That is, to develop
      treatments for smokers not yet ready to quit, those who are preparing to quit, those actively
      engaged in the quitting process and those who have tried to quit but relapsed. To achieve
      this goal, this research comprises three distinct research studies, each of which represent a
      phase in a comprehensive chronic care treatment model for clinical intervention with smokers
      in the primary care setting: the Motivation Study, the Cessation Study, and the Long-term
      Quitting Study. The goal of each study is to test and identify effective intervention
      components for distinct phases of the smoking cessation process. These components will then
      be combined for future research on the effectiveness of this chronic care treatment package
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abstinence From Smoking</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>The outcome measure consists of the number of participants reporting abstinence from smoking at 6 months that is biochemically confirmed (exhaled carbon monoxide &lt; 6 parts per million).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">623</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Modern Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abstinence-Optimized Cessation Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>8 weeks of nicotine patch</description>
    <arm_group_label>Modern Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>in-person counseling and quitline counseling</intervention_name>
    <description>a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website</description>
    <arm_group_label>Modern Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preparation Nicotine Mini-Lozenges</intervention_name>
    <description>Nicotine lozenge prior to attempting to quit smoking</description>
    <arm_group_label>Abstinence-Optimized Cessation Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination NRT (nicotine patch + nicotine mini-lozenges)</intervention_name>
    <description>26 weeks of combination NRT as part of a quit smoking attempt</description>
    <arm_group_label>Abstinence-Optimized Cessation Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive In-Person Cessation Counseling</intervention_name>
    <description>three 20-min In-person Cessation Counseling sessions</description>
    <arm_group_label>Abstinence-Optimized Cessation Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Extended Maintenance Counseling Calls</intervention_name>
    <description>8 Maintenance-phase smoking cessation counseling sessions</description>
    <arm_group_label>Abstinence-Optimized Cessation Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Automated Adherence Calls</intervention_name>
    <description>11 brief, automated calls reminding them to use their medications properly</description>
    <arm_group_label>Abstinence-Optimized Cessation Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;=18 years

          -  smoking &gt;4 cigarettes/day for the previous 6 months

          -  able to read, write, and speak English

          -  have reliable phone access and agree to respond to Interactive Voice Response (IVR)
             phone prompts

          -  and if currently using NRT, agreeing to use only study medication for the duration of
             the study

          -  we will not exclude participants based on their prior use of cessation medication or
             if they use multiple tobacco products in order to enhance real-world generalization
             (these will be statistically controlled in analyses)

          -  not currently attempting to quit smoking

          -  not intending to quit smoking (defined as no plans to quit in the next month)

          -  and planning to remain in the intervention catchment area for at least 12 months.

        Exclusion Criteria:

          -  currently taking bupropion or varenicline

          -  medical contraindications to using NRT including hospitalized (for at least one night)
             for a stroke, heart attack, congestive heart failure or diabetes in the last 30 days

          -  diagnosis of or treatment for schizophrenia, a psychotic disorder or bipolar disorder
             in the last 10 years

          -  and, if the participant is a woman of childbearing potential, being pregnant or
             intending to becoming pregnant or unwillingness to use an approved method of birth
             control during treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan Piper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctri.wisc.edu/</url>
    <description>Description: University of Wisconsin Center for Tobacco Research and Intervention</description>
  </link>
  <results_reference>
    <citation>Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Collins LM, Mermelstein R, Fraser D, Fiore MC, Baker TB. A Randomized Controlled Trial of an Optimized Smoking Treatment Delivered in Primary Care. Ann Behav Med. 2018 Sep 13;52(10):854-864. doi: 10.1093/abm/kax059.</citation>
    <PMID>30212849</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <results_first_submitted>March 8, 2019</results_first_submitted>
  <results_first_submitted_qc>April 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2019</results_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>cessation</keyword>
  <keyword>tobacco</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02301403/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02301403/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were patients from seven primary care clinics within two Wisconsin healthcare systems. Smokers who expressed interest in quitting smoking during a clinic visit were referred via the electronic health record (EHR) to the research study. Other smokers from these clinics were recruited via mailings and EHR messaging.</recruitment_details>
      <pre_assignment_details>Primary care patients who passed the phone screen were invited to attend a study visit at their referring clinic to learn more about the study, have eligibility confirmed, and provide written informed consent. No enrolled participants were excluded from the study prior to assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Modern Usual Care</title>
          <description>Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
Nicotine patch: 8 weeks of nicotine patch
in-person counseling and quitline counseling: a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website</description>
        </group>
        <group group_id="P2">
          <title>Abstinence-Optimized Cessation Treatment</title>
          <description>There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
Preparation Nicotine Mini-Lozenges: Nicotine lozenge prior to attempting to quit smoking
Combination NRT (nicotine patch + nicotine mini-lozenges): 26 weeks of combination NRT as part of a quit smoking attempt
Intensive In-Person Cessation Counseling: three 20-min In-person Cessation Counseling sessions
Extended Maintenance Counseling Calls: 8 Maintenance-phase smoking cessation counseling sessions
Automated Adherence Calls: 11 brief, automated calls reminding them to use their medications properly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="267"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modern Usual Care</title>
          <description>Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
Nicotine patch: 8 weeks of nicotine patch
in-person counseling and quitline counseling: a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website</description>
        </group>
        <group group_id="B2">
          <title>Abstinence-Optimized Cessation Treatment</title>
          <description>There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
Preparation Nicotine Mini-Lozenges: Nicotine lozenge prior to attempting to quit smoking
Combination NRT (nicotine patch + nicotine mini-lozenges): 26 weeks of combination NRT as part of a quit smoking attempt
Intensive In-Person Cessation Counseling: three 20-min In-person Cessation Counseling sessions
Extended Maintenance Counseling Calls: 8 Maintenance-phase smoking cessation counseling sessions
Automated Adherence Calls: 11 brief, automated calls reminding them to use their medications properly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="315"/>
            <count group_id="B2" value="308"/>
            <count group_id="B3" value="623"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="12.9"/>
                    <measurement group_id="B2" value="50.0" spread="12.5"/>
                    <measurement group_id="B3" value="49.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abstinence From Smoking</title>
        <description>The outcome measure consists of the number of participants reporting abstinence from smoking at 6 months that is biochemically confirmed (exhaled carbon monoxide &lt; 6 parts per million).</description>
        <time_frame>6 months post treatment</time_frame>
        <population>Adult smokers interested in quitting smoking who met inclusion and exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Modern Usual Care</title>
            <description>Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
Nicotine patch: 8 weeks of nicotine patch
in-person counseling and quitline counseling: a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website</description>
          </group>
          <group group_id="O2">
            <title>Abstinence-Optimized Cessation Treatment</title>
            <description>There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
Preparation Nicotine Mini-Lozenges: Nicotine lozenge prior to attempting to quit smoking
Combination NRT (nicotine patch + nicotine mini-lozenges): 26 weeks of combination NRT as part of a quit smoking attempt
Intensive In-Person Cessation Counseling: three 20-min In-person Cessation Counseling sessions
Extended Maintenance Counseling Calls: 8 Maintenance-phase smoking cessation counseling sessions
Automated Adherence Calls: 11 brief, automated calls reminding them to use their medications properly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abstinence From Smoking</title>
          <description>The outcome measure consists of the number of participants reporting abstinence from smoking at 6 months that is biochemically confirmed (exhaled carbon monoxide &lt; 6 parts per million).</description>
          <population>Adult smokers interested in quitting smoking who met inclusion and exclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for participants using the nicotine patch during 8 weeks of active patch treatment. Adverse event data was collected for participants using the nicotine patch and nicotine mini-lozenge during 26 weeks of active use of these 2 medications post-quit.</time_frame>
      <desc>Adverse events (AEs) and serious AEs (SAEs) were assessed with the question “Since your last contact with us, have there been any changes in your medical condition or health?”
For each nicotine-medication-related symptom reported, severity was assessed and whether the symptom has resolved.
For any non-nicotine-medication-related symptoms that are reported as a concern, participants were advised to contact their primary care provider in the clinic as per IRB approval.</desc>
      <group_list>
        <group group_id="E1">
          <title>Modern Usual Care</title>
          <description>Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
Nicotine patch: 8 weeks of nicotine patch
in-person counseling and quitline counseling: a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website</description>
        </group>
        <group group_id="E2">
          <title>Abstinence-Optimized Cessation Treatment</title>
          <description>There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
Preparation Nicotine Mini-Lozenges: Nicotine lozenge prior to attempting to quit smoking
Combination NRT (nicotine patch + nicotine mini-lozenges): 26 weeks of combination NRT as part of a quit smoking attempt
Intensive In-Person Cessation Counseling: three 20-min In-person Cessation Counseling sessions
Extended Maintenance Counseling Calls: 8 Maintenance-phase smoking cessation counseling sessions
Automated Adherence Calls: 11 brief, automated calls reminding them to use their medications properly</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="315"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Persistent Indigestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Mouth Problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Itching or Hives</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="315"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="315"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="315"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stevens S. Smith, Ph.D.</name_or_title>
      <organization>Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health</organization>
      <phone>6082627563</phone>
      <email>sss@ctri.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

